Literature DB >> 26246483

Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts.

Kristie D Goughenour1, Joan-Miquel Balada-Llasat2, Chad A Rappleye3.   

Abstract

Standardized methodologies for determining the antifungal susceptibility of fungal pathogens is central to the clinical management of invasive fungal disease. Yeast-form fungi can be tested using broth macrodilution and microdilution assays. Reference procedures exist for Candida species and Cryptococcus yeasts; however, no standardized methods have been developed for testing the antifungal susceptibility of yeast forms of the dimorphic systemic fungal pathogens. For the dimorphic fungal pathogen Histoplasma capsulatum, susceptibility to echinocandins differs for the yeast and the filamentous forms, which highlights the need to employ Histoplasma yeasts, not hyphae, in antifungal susceptibility tests. To address this, we developed and optimized methodology for the 96-well microtiter plate-based measurement of Histoplasma yeast growth in vitro. Using optical density, the assay is quantitative for fungal growth with a dynamic range greater than 30-fold. Concentration and assay reaction time parameters were also optimized for colorimetric (MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduction) and fluorescent (resazurin reduction) indicators of fungal vitality. We employed this microtiter-based assay to determine the antifungal susceptibility patterns of multiple clinical isolates of Histoplasma representing different phylogenetic groups. This methodology fulfills a critical need for the ability to monitor the effectiveness of antifungals on Histoplasma yeasts, the morphological form present in mammalian hosts and, thus, the form most relevant to disease.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26246483      PMCID: PMC4572531          DOI: 10.1128/JCM.00795-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  44 in total

1.  Studies on the growth of Histoplasma capsulatum. I. Growth of the yeast phase in liquid media.

Authors:  L PINE
Journal:  J Bacteriol       Date:  1954-12       Impact factor: 3.490

2.  Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole.

Authors:  L Joseph Wheat; Patricia Connolly; Melinda Smedema; Michelle Durkin; Edward Brizendine; Paul Mann; Reena Patel; Paul M McNicholas; Mitchell Goldman
Journal:  J Antimicrob Chemother       Date:  2006-04-20       Impact factor: 5.790

Review 3.  Endemic mycoses: overlooked causes of community acquired pneumonia.

Authors:  Chadi A Hage; Kenneth S Knox; Lawrence J Wheat
Journal:  Respir Med       Date:  2012-03-03       Impact factor: 3.415

4.  Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin.

Authors:  David van Duin; Arturo Casadevall; Joshua D Nosanchuk
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 5.  Histoplasma mechanisms of pathogenesis--one portfolio doesn't fit all.

Authors:  Jessica A Edwards; Chad A Rappleye
Journal:  FEMS Microbiol Lett       Date:  2011-08-09       Impact factor: 2.742

6.  Quantitative plating of Histoplasma capsulatum without addition of conditioned medium or siderophores.

Authors:  P L Worsham; W E Goldman
Journal:  J Med Vet Mycol       Date:  1988-06

7.  Cysteine biosynthesis in a fungus, Histoplasma capsulatum.

Authors:  D A Stetler; G Boguslawski
Journal:  Sabouraudia       Date:  1979-03

8.  In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.

Authors:  Gloria M González
Journal:  Med Mycol       Date:  2008-12-18       Impact factor: 4.076

9.  Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum.

Authors:  Jessica A Edwards; Megan M Kemski; Chad A Rappleye
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

10.  Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice.

Authors:  P Connolly; J Wheat; C Schnizlein-Bick; M Durkin; S Kohler; M Smedema; J Goldberg; E Brizendine; D Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  15 in total

1.  Eng1 and Exg8 Are the Major β-Glucanases Secreted by the Fungal Pathogen Histoplasma capsulatum.

Authors:  Andrew L Garfoot; Kacey L Dearing; Andrew D VanSchoiack; Vicki H Wysocki; Chad A Rappleye
Journal:  J Biol Chem       Date:  2017-02-02       Impact factor: 5.157

2.  Antifungal therapeutics for dimorphic fungal pathogens.

Authors:  Kristie D Goughenour; Chad A Rappleye
Journal:  Virulence       Date:  2016-09-19       Impact factor: 5.882

Review 3.  Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).

Authors:  Edinaira Sulany Oliveira de Sousa; Ana Claúdia Alves Cortez; Marcia de Souza Carvalho Melhem; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-08-05       Impact factor: 2.476

4.  The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Authors:  Kristy Koselny; Julianne Green; Louis DiDone; Justin P Halterman; Annette W Fothergill; Nathan P Wiederhold; Thomas F Patterson; Melanie T Cushion; Chad Rappelye; Melanie Wellington; Damian J Krysan
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

5.  In Vitro Antifungal Susceptibility of Yeast and Mold Phases of Isolates of Dimorphic Fungal Pathogen Emergomyces africanus (Formerly Emmonsia sp.) from HIV-Infected South African Patients.

Authors:  Tsidiso G Maphanga; Erika Britz; Thokozile G Zulu; Ruth S Mpembe; Serisha D Naicker; Ilan S Schwartz; Nelesh P Govender
Journal:  J Clin Microbiol       Date:  2017-03-29       Impact factor: 5.948

6.  O-Mannosylation of Proteins Enables Histoplasma Yeast Survival at Mammalian Body Temperatures.

Authors:  Andrew L Garfoot; Kristie D Goughenour; Marcel Wüthrich; Murugesan V S Rajaram; Larry S Schlesinger; Bruce S Klein; Chad A Rappleye
Journal:  mBio       Date:  2018-01-02       Impact factor: 7.786

7.  Genome Sequences Reveal Cryptic Speciation in the Human Pathogen Histoplasma capsulatum.

Authors:  Victoria E Sepúlveda; Roberto Márquez; David A Turissini; William E Goldman; Daniel R Matute
Journal:  mBio       Date:  2017-12-05       Impact factor: 7.867

8.  A modular yeast biosensor for low-cost point-of-care pathogen detection.

Authors:  Nili Ostrov; Miguel Jimenez; Sonja Billerbeck; James Brisbois; Joseph Matragrano; Alastair Ager; Virginia W Cornish
Journal:  Sci Adv       Date:  2017-06-28       Impact factor: 14.136

9.  Concentration-dependent protein loading of extracellular vesicles released by Histoplasma capsulatum after antibody treatment and its modulatory action upon macrophages.

Authors:  Ludmila Matos Baltazar; Daniel Zamith-Miranda; Meagan C Burnet; Hyungwon Choi; Leonardo Nimrichter; Ernesto S Nakayasu; Joshua D Nosanchuk
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

10.  Recent admixture between species of the fungal pathogen Histoplasma.

Authors:  Colin S Maxwell; Victoria E Sepulveda; David A Turissini; William E Goldman; Daniel R Matute
Journal:  Evol Lett       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.